SCHEMBL186050

SCHEMBL186050

Cc1ccc(C(=O)NC2(C(=O)NCc3ccc(Nc4ccc(F)cc4C(F)(F)F)cn3)CC2)cn1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.36
HDAC1 Q13547 4/20 0.36
HDAC3 O15379 3/20 0.36
HDAC2 Q92769 3/20 0.36
BDKRB1 P46663 1/20 0.36
HDAC6 Q9UBN7 2/20 0.35
GRM5 P41594 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
P2RX7 Q99572 2/20 0.35
TNK2 Q07912 2/20 0.35
MAP4K2 Q12851 2/20 0.35
KCNQ3 O43525 1/20 0.35
KCNQ2 O43526 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PTK2 Q05397 1/20 0.34
CNR2 P34972 1/20 0.34
BACE1 P56817 1/20 0.34
TRPA1 O75762 1/20 0.34
NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL186523 0.92 RAB9A (0.39) CNR1BDKRB1GRM5P2RX7TNK2
SCHEMBL185963 0.92 FPR2 (0.39) CNR1HDAC1BDKRB1HDAC6GRM5
SCHEMBL2811921 0.92 HDAC3 (0.38) HDAC1HDAC3HDAC2BDKRB1HDAC6
SCHEMBL185570 0.91 ALDH1A1 (0.36) HDAC1HDAC3HDAC2BDKRB1HDAC6
SCHEMBL186730 0.91 TRPA1 (0.40) HDAC1HDAC3HDAC2BDKRB1HDAC6
SCHEMBL186398 0.90 HDAC1 (0.35) HDAC1HDAC3HDAC2BDKRB1HDAC6
SCHEMBL186387 0.90 KCNQ3 (0.42) HDAC1HDAC3HDAC2BDKRB1HDAC6
SCHEMBL185915 0.90 ABL1 (0.38) HDAC1HDAC3HDAC2BDKRB1HDAC6
SCHEMBL2807486 0.89 HDAC3 (0.41) HDAC1HDAC3HDAC2BDKRB1HDAC6
SCHEMBL186506 0.88 AR (0.38) HDAC1HDAC3HDAC2HDAC6KCNQ3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
EP-2401256-B1 Compounds as bradykinin B1 antagonists BOEHRINGER INGELHEIM INT (DE) 2013-04-17 EP disclosed
EP-2401256-B1 Compounds as bradykinin B1 antagonists BOEHRINGER INGELHEIM INT (DE) 2013-04-17 EP disclosed
EP-2401256-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-01-04 EP disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
WO-2010097372-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO disclosed
WO-2010097372-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131075-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 CNR1 211/4885HDAC1 1428/4885HDAC3 1696/4885
US-20100240669-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 CNR1 211/4885HDAC1 1428/4885HDAC3 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.